Terameprocol - Erimos Pharmaceuticals

Drug Profile

Terameprocol - Erimos Pharmaceuticals

Alternative Names: CINelim; EM-1421; M4N; NSC 136955; Tetra-O-methyl nordihydroguaiaretic acid; Tetra-O-methyl-NDGA; Tetramethoxynordihydroguaiaretic acid; TMNDGA

Latest Information Update: 03 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johns Hopkins University
  • Developer Erimos Pharmaceuticals
  • Class Antineoplastics; Lignans; Small molecules
  • Mechanism of Action Apoptosis stimulants; BIRC5 protein inhibitors; Cdc2 kinase inhibitors; Mitosis inhibitors; Transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Bacterial infections; Cervical intraepithelial neoplasia; Diabetes mellitus; Glioma; Haematological malignancies; Head and neck cancer; Herpes simplex virus infections; HIV infections; Human papillomavirus infections; Influenza virus infections; Leukaemia; Obesity; Psoriasis; Solid tumours

Most Recent Events

  • 21 Nov 2017 Sidney Kimmel Comprehensive Cancer Center and Erimos Pharmaceuticals plans a phase I trial for Glioma (Recurrent, Metastatic disease, Late stage disease, Second-line therapy or greater) in USA, in December 2017 (PO) (NCT02575794)
  • 09 Oct 2015 Sidney Kimmel Comprehensive Cancer Center and Erimos Pharmaceuticals plan a phase I trial for Glioma in USA (NCT02575794)
  • 04 Aug 2015 No recent reports on development identified - Phase-I/II for Glioma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top